$0.40
-0.02 (-5.36%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ANEB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational
Held by 0 tracked-famous managers · FINRA short interest 6.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Observational Study of THC Concentrations in Acute Cannabis-induced CNS DepressionNCT06017622observationalPlasma Concentration of delta-9 tetrahydrocannabinol (THC) | — | Recruiting | — | Acute Cannabis-induced CNS Depression | 36 | 2026-12-30 | in 133 d | 2026-07-30 |
| I.V. Selonabant in Healthy Adult SubjectsNCT07211607Number of Participants with Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: selonabant, placebo | Healthy Volunteers | 40 | 2026-05-06actual | — | 2026-05-08 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge TestNCT05282797Subjective Feeling HighRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ANEB-001, Placebo | Acute Cannabinoid Intoxication | 154 | 2023-08-26actual | — | 2023-08-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19